Vertex Pharmaceuticals
Prezzo: 444.93Società e modello di business
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases, primarily cystic fibrosis. Its core products include Kalydeco, Orkambi, Symdeko, and Trikafta, which target the underlying causes of cystic fibrosis. The company generates revenue mainly from product sales and has a strong pipeline of potential therapies in various stages of development.
Profilo di investimento
The investment profile of Vertex Pharmaceuticals is more aligned with growth investors, given its focus on innovation and potential for future revenue expansion through new therapies. The absence of dividends suggests a reinvestment strategy aimed at long-term growth. The stock may appeal to those with a medium to long-term investment horizon, while its moderate volatility indicates a need for a basic level of market experience.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 17.01 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -7.4% ↓
- Sorpresa EPS
- 5.4% meglio del previsto
- Volatilità 20g
- 1.6% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-11 05:28 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-16 02:35 | Compra | Mantieni | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-14 02:35 | Vendi | Compra | Mixed performance; watch for recovery signs. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-27 05:02 | Truist Financial | Aggiorna | — → 542 | 435.93 |
| 2026-05-06 09:48 | Barclays | Target alzato | 607 → 615 | 424.36 |
| 2026-05-05 12:24 | Morgan Stanley | Target alzato | 612 → 616 | 417.72 |
Ancora nulla